Sanofi Canada Statement in response to INESSS Decision Impacting Prostate
Cancer Patients in Quebec
MONTREAL, March 27, 2013 /CNW Telbec/ - "It is with great disappointment that
Sanofi Canada has learned that the Institut national d'excellence en santé et
en services sociaux (INESSS) has not approved the public listing of JEVTANA®
(cabazitaxel)," said Jon Fairest, President and CEO of Sanofi Canada. "This
decision means that those men living with prostate cancer in Quebec and
dependent on the public system will not have access to public reimbursement
The provinces of Alberta, Saskatchewan, Manitoba and Ontario have already
approved and recognized the value of JEVTANA® for patients living in these
Sanofi Canada's ambition is to bring value, health and hope to Canadians
through innovative healthcare solutions. Sanofi Canada stands behind the
principle of access to the right medicine for the right patient at the right
time, in strict accordance with advice and oversight from the appropriate
"It is an exciting time in the area of prostate cancer research with several
new treatment options recently approved by Health Canada. Scientific
research and clinical evidence suggests that there are subgroups of patients
who respond differently to these different treatment options, therefore, the
ability to individualize treatment is what is necessary to provide best
outcomes for patients ," added Mr. Fairest. "Not having Cabazitaxel available
to physicians and patients as a treatment option is extremely disappointing.
We can just begin to imagine how frustrating this will be for patients and
their families. New drugs with recognized therapeutic value need to be
accessible to patients and clinicians in order to accomplish the objective and
offer the best chance of extending survival."
Regardless of therecent decision by INESSS to not approve JEVTANA®, Sanofi
hopesto have the opportunity to work with INESSS in the very near future to
help make this unique treatment option available to prostate cancer patients
who can benefit from it.
JEVTANA® is a second line treatment of castration resistant (hormone
refractory) metastatic prostate cancer (mHRPC) in combination with prednisone
in patients who have received prior treatment with a docetaxel containing
Jevtana® is a registered trademark of Sanofi.
Sanofi, a global and diversified healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi companies in Canada include sanofi-aventis Canada Inc.
(pharmaceuticals), Sanofi Pasteur (vaccines), Sanofi Consumer Health (health
and beauty), Genzyme (rare diseases) and Merial (animal health). Together they
employ more than 1,700 people, mainly in the greater Montreal and Toronto
areas. In 2011 Sanofi companies invested $151.7 million in R&D in Canada,
creating jobs, business and opportunity throughout the country. For additional
information, please visit http://www.sanofi.ca .
MEDIA Caroline Martel Communications Consultant, Sanofi Canada 514-956-6120
SOURCE: Canadian Cancer Survivor Network (CCSN)
To view this news release in HTML formatting, please use the following URL:
CO: Canadian Cancer Survivor Network (CCSN)
NI: HEA HEA
-0- Mar/27/2013 20:45 GMT
Press spacebar to pause and continue. Press esc to stop.